This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Quidel Passes the Test

Click here for an archive of Cramer's "Mad Money" recaps.

In order to stop the flu, you need to be able to diagnose it quickly, which is why Jim Cramer told viewers of his "Mad Money" TV show on Friday that he likes diagnostic-test maker Quidel (QDEL - Get Report), as a play on avian flu.

There's not enough flu vaccine, said Cramer, so a speedy and effective diagnostic tool is paramount in the fight against the flu, said Cramer.

Quidel is profitable and stands a good chance to make a lot of money from its test, said Cramer. Nevertheless, the most important thing Quidel has going for it is the "buzz" that will be sustained "as we keep talking about the flu."

A caller asked if flu concerns might hurt holiday travel, thus making travel companies potential short candidates. Cramer said he didn't believe so as both Priceline.com (PCLN - Get Report) and Expedia (EXPE - Get Report) recently said the travel business has picked up. Gas prices have turned down, he said, and that trumps flu concerns.

Another caller asked if Yum! Brands (YUM - Get Report), which owns Kentucky Fried Chicken, might see slowing growth in China as a result of bird flu. Cramer said as a play on China, he would swap out of Yum! and into Starbucks (SBUX - Get Report) regardless of avian flu concerns because Starbucks is "right where Yum! was two years ago" in China, and it has even more growth ahead of it there than Yum! does at this point.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs